Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

Nodular Basal Cell Carcinoma Clinical Trial

Official title:
Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

Status Terminated

Clinical Trial Summary

The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01808950
Study type	Interventional
Source	Spirig Pharma Ltd.
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	January 2013
Completion date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04552990` - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma	Phase 2
Completed	`NCT02270645` - Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser	N/A
Completed	`NCT02018679` - Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma	Phase 1
Recruiting	`NCT05157763` - A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma	Phase 1/Phase 2
Active, not recruiting	`NCT02242929` - Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma	Phase 3
Recruiting	`NCT04744935` - Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma	N/A
Completed	`NCT04470726` - Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma	Phase 1/Phase 2